Loss and revival of androgen receptor signaling in advanced prostate cancer
- Formaggio, Nicolò Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
- Rubin, Mark A. Department for BioMedical Research and Bern Center of Precision Medicine, University of Bern and Inselspital, Bern, Switzerland
- Theurillat, Jean-Philippe Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
-
2020
Published in:
- Oncogene. - Springer. - 2021, vol. 40, no. 7, p. 1205–1216
English
Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens have emerged and have been successfully i mplemented in clinical practice. That said, the stronger inhibition of the AR signaling axis has led in recent years to an increase of prostate cancers that de-differentiate into AR-negative disease. Unfortunately, this process is intimately linked with a poor prognosis. Here, we review the molecular mechanisms that enable cancer cells to switch from an AR-positive to an AR-negative disease and efforts to prevent/revert this process and thereby maintain/restore AR-dependence.
- Language
-
- English
- Classification
- Medicine
- License
- CC BY
- Open access status
- hybrid
- Identifiers
-
- RERO DOC 333620
- DOI 10.1038/s41388-020-01598-0
- ARK ark:/12658/srd1319390
- Persistent URL
- https://n2t.net/ark:/12658/srd1319390
Statistics
Document views: 84
File downloads:
- Theurillat_o_2020.pdf: 188